Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Your donations help support people living with type 1 diabetes today and fund the best treatment and cure research, no matter where in the world it takes place.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
Join the type 1 diabetes community and come together, raise awareness and vital funds for T1D. Every step taken and pound raised directly supports us to fund our life-changing research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & events > News > Omnipod 5 becomes the latest hybrid closed loop system available in the UK
Insulet, the company who make Omnipod® products, has announced that their Omnipod® 5 hybrid closed loop (HCL) technology is now available in the UK.
Omnipod 5 is the first tubeless hybrid closed loop system. The pod-style insulin pump integrates with the Dexcom G6 continuous glucose monitor (CGM) via the Omnipod 5 Controller.
Omnipod 5 has an integrated algorithm called the ‘SmartBolus Calculator’, which automatically responds to your CGM glucose value and trend, so you don’t have to. It also comes with an activity feature which, when enabled, reduces insulin delivery, and raises the glucose target in situations where you need less insulin, for example when exercising.
Similar to the Omnipod DASH, the insulin pump in the Omnipod 5 system is a new version of Insulet’s wireless pod-style pumps. The new pump in the Omnipod 5 system is waterproof and enhanced with SmartAdjust™ technology. The device automatically increases, decreases, or pauses basal insulin delivery every five minutes based on your personal target glucose levels.
The Omnipod 5 HCL system only works with the Dexcom G6 sensor. This CGM has shareability and alert features. Dexcom D6 is available on the NHS through your diabetes clinic or can be purchased separately from the Omnipod 5.
The National Institute for Health and Care Excellence (NICE, the body which advises the NHS on treatments and technologies), is currently reviewing its recommendations for HCL technology to be made available on the NHS. We are expecting NICE’s final decision in September.
Omnipod 5 is now available on the NHS frameworks and Insulet is working with NHS Trusts to make Omnipod 5 available locally as rapidly as possible. Please check availability with your local diabetes team at your next planned consultation. Insulet also has a team dedicated to support you with this and product related queries. you can contact Insulet by calling 0800 011 6132 and pressing option 4 or by emailing omnipodinfogb@insulet.com.
The Omnipod 5 HCL system is approved for people with type 1 diabetes who are aged 2 years and older.
“With NICE set to recommend hybrid closed loop in England and Wales later this year, we are delighted that more hybrid closed loop systems such as the Omnipod 5 are becoming available to help people manage their type 1 diabetes. Diabetes management is very personal, so access to a range of technology options is crucial. A wider choice of hybrid closed loop systems offers people with type 1 evidence-based technology they can trust to support them to manage their condition with confidence.”
In an historic advancement in the treatment of type 1 diabetes, the National Institute for Health and Care Excellence (NICE) today approves hybrid closed loop for the majority of people living with type 1 diabetes in England and Wales.
As part of its assessment of hybrid closed loop (HCL), the National Institute for Health and Care Excellence (NICE) has today published an additional consultation on its roll out.
Abbott has announced that its FreeStyle Libre® 3 sensor is now authorised to work with Ypsomed’s mylife™ YpsoPump and CamDiab’s CamAPS FX mobile app.
